Studienregister

allo-APZ2-CVU-III

A Pivotal, Randomized, Placebo-controlled, Double-blind, Multicenter, International Phase III Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Non-Healing Chronic Venous Ulcers (CVU)

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

NCT-Nummer: NCT06489028

ARCHITECT

Non-Interventionelle ADOREG Registerstudie zur Charakterisierung einer Kombination aus Immuntherapie und Elektrochemotherapie beim malignen Melanom

Berufsordnung (BO) / Nicht-interventionell

CFT1946-1101

A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of Cft1946 as Monotherapy and in Combination with Trametinib in Subjects with Braf-V600 Mutant Solid Tumors

Arzneimittelgesetz (AMG) / Phase 1, Interventionell, Multizentrisch

NCT-Nummer: NCT05668585

D346BC00001 LAVENDER

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Animalarial Therapy

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

EudraCT-Nummer: 2021-003698-70

NCT-Nummer: NCT06015737

DICIT

Efficacy of diclofenac added to ongoing PD-1 inhibitor therapy in metastatic melanoma patients

Arzneimittelgesetz (AMG) / Phase 2, Interventionell

Efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved stable disease as best response in metastatic melanoma patients. A single arm phase II trial

GSK 219538

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in adult participants with Moderate to Severe Atopic Dermatitis

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in Adult Participants with Moderate to Severe Atopic Dermatitis

NCT-Nummer: NCT05999799

IFX-1-P3.4

A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum.

Arzneimittelgesetz (AMG) / Phase 3, Interventionell, Multizentrisch

NCT-Nummer: NCT05964413

IMA402-101

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA402, a Bispecific T Cell Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

Arzneimittelgesetz (AMG) / Phase 1, Interventionell, Multizentrisch

IMC-F106C-301

A Phase 3 Randomized, Controlled Study of IMC-F 106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

NCT-Nummer: NCT06112314

IMCgp100-203

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

Arzneimittelgesetz (AMG) / Phase 2, Interventionell, Multizentrisch

EudraCT-Nummer: 2022-502732-39-00

NCT-Nummer: NCT05549297

M1095-HS-301 MoonLake

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa

Clinical Trial Regulation (CTR) / Interventionell

M1095-PPP-201

A Phase 2, multicentre open-label study to explore the effects of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

SKABUP

Multizentrische, prospektive, randomisierte, doppelblinde Phase III-Studie zum Vergleich der Wirksamkeit und Sicherheit der Therapie der Skabies mit zwei unterschiedlich konzentrierten Permethrin-Cremes

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

23-BI-1607-02

AN OPEN-LABEL, MULTICENTRE PHASE 1B/2A CLINICAL TRIAL OF BI-1607, AN FC-ENGINEERED MONOCLONAL ANTIBODY TO FCyRIIB (CD32B), IN COMBINATION WITH IPILIMUMAB AND PEMBROLIZUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

Das Studienregister der UME

- Klinik für Dermatologie -

Aktuelle Studien

allo-APZ2-CVU-III

A Pivotal, Randomized, Placebo-controlled, Double-blind, Multicenter, International Phase III Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Non-Healing Chronic Venous Ulcers (CVU)

ARCHITECT

Non-Interventionelle ADOREG Registerstudie zur Charakterisierung einer Kombination aus Immuntherapie und Elektrochemotherapie beim malignen Melanom

CFT1946-1101

A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of Cft1946 as Monotherapy and in Combination with Trametinib in Subjects with Braf-V600 Mutant Solid Tumors

D346BC00001 LAVENDER

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Animalarial Therapy

DICIT

Efficacy of diclofenac added to ongoing PD-1 inhibitor therapy in metastatic melanoma patients

GSK 219538

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in adult participants with Moderate to Severe Atopic Dermatitis

IFX-1-P3.4

A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum.

IMA402-101

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA402, a Bispecific T Cell Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

IMC-F106C-301

A Phase 3 Randomized, Controlled Study of IMC-F 106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

IMCgp100-203

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

M1095-HS-301 MoonLake

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa

M1095-PPP-201

A Phase 2, multicentre open-label study to explore the effects of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris

SKABUP

Multizentrische, prospektive, randomisierte, doppelblinde Phase III-Studie zum Vergleich der Wirksamkeit und Sicherheit der Therapie der Skabies mit zwei unterschiedlich konzentrierten Permethrin-Cremes

23-BI-1607-02

AN OPEN-LABEL, MULTICENTRE PHASE 1B/2A CLINICAL TRIAL OF BI-1607, AN FC-ENGINEERED MONOCLONAL ANTIBODY TO FCyRIIB (CD32B), IN COMBINATION WITH IPILIMUMAB AND PEMBROLIZUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA